EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
← Back to the desk

Provenance / RESEARCH BRIEFING

GLP-1 pharmacy supplier due-diligence checklist

Build a claim-to-evidence register covering identity, product scope, distribution and exception handling.

THE FINDING

Registration is a scoped facility fact, not a product approval or an assurance of present compliance.

Affected arrangements: Buyers assessing a dispensing pharmacy, outsourcing facility or procurement platform.

Resolve identity before reputation

Collect the contracting entity, operating names, physical facility and the actual source of the proposed medicine. Reconcile the names across the quotation, licence records and contract. A platform's brand and the dispensing entity may differ. Each material claim should have an evidence link, date and named owner rather than a general vetted label.

Read facility evidence precisely

FDA states that outsourcing registration does not mean a facility makes approved drugs or meets all applicable requirements. Inspection evidence is also scoped to a facility and a point in time. Keep registration, inspection observations, responses, recalls and final actions distinct. Missing information is not proof of an adverse finding, but it remains a question for the buyer.

Test the operational particulars

Request product provenance, applicable tracing responsibilities, destination permissions, temperature controls, delivery exceptions and complaint escalation. Ask for the procedure and the scope it covers rather than a marketing assertion. For capacity, retain the supplier's statement with its date, volume and exclusions; a licence does not establish allocation or capacity.

Export an evidence register

Use columns for claim, document, evidence date, status, implication, reviewer and next action. Mark entries supplier-reported, not checked or requires review as appropriate. Only label a source checked when the specific source has actually been inspected. Keep clinical and legal decisions assigned to qualified reviewers. The output is a defensible record of questions, not a supplier endorsement.

Questions to take forward

  • Does the document identify the same facility as the contract?
  • What evidence supports the claimed product provenance?
  • Who investigates a temperature excursion or suspected counterfeit?
Put this briefing to work

Primary sources & evidence limits

FDA: Outsourcing facility registration questions and answers ↗Publication date not confirmed · Accessed 2026-11-17FDA: Concerns with unapproved GLP-1 drugs ↗Publication date not confirmed · Accessed 2026-11-17

Primary-source links were opened or retrieved on 17 November 2026. This date records source access, not legal or clinical review. Procurement checklists and commercial models are editorial methods. No live supplier, licence, coverage or capacity verification has been performed.

Read the research methodology →